Target: Galderma Group AG, relevant subsidiaries, controlling principals, and verified commercial partners Research date: 25 October 2026 Scope: Enterprise technology, digital systems, AI, data residency, Israeli technology relationships, and relevant supply-chain disclosures.
Enterprise Technology Stack & Vendor Relationships
Israeli-origin enterprise software
No public evidence identified establishing Galderma’s direct licensing, subscription, procurement, or deployment of Check Point, Wiz, CyberArk, SentinelOne, NICE, Verint, Claroty, Palo Alto Networks, or other named Israeli-origin cybersecurity or enterprise software vendors.
Documented digital technology partner - Crisalix
On 26 January 2023, Galderma announced the launch of FACE by Galderma, an augmented-reality aesthetic consultation application developed in partnership with Crisalix; the platform supports facial assessment, treatment planning, and simulated injectable outcomes, with a planned international rollout during 2023.1
Galderma’s 22 March 2023 US announcement independently identified Crisalix as the technology developer and described real-time treatment simulation and patient access to individual profiles.2
Galderma continued discussing FACE as an example of its dermatology technology strategy in 2024, although the public statement did not establish a current Israeli technology or hosting relationship.3
No public evidence identified establishing that Crisalix supplied Israeli-origin technology or that its Galderma implementation used infrastructure within Israeli jurisdiction.
Enterprise IT and internal technology functions
In a 2025 corporate technology feature, Galderma identified Jason Goddard as Global Head of IT and Edoardo Tersigni as its Automation and AI lead; the article describes an AI Framework, AI Center of Excellence, predictive and generative AI projects, and IT support for the company’s R&D infrastructure.4
Galderma’s 2023 CEO statement described investment in digital tools, healthcare-professional engagement, loyalty programmes, FACE by Galderma, and Cetaphil AI Skin Analysis.5
No public evidence identified establishing a named Israeli-origin enterprise technology supplier within these internal programmes.
Israeli commercial and licensing relationships
On 28 June 2021, Galderma and Israeli company Sol-Gel Technologies announced exclusive US commercialisation licences for EPSOLAY and TWYNEO, incorporating Sol-Gel’s proprietary microencapsulation pharmaceutical technology; the announced financial terms included potential upfront and approval payments of up to $15 million and tiered royalties.6
Sol-Gel’s 2024 annual filing reported $11 million received in upfront and regulatory approval milestone payments and described continuing royalties under the arrangements.7
An SEC-filed termination agreement established that the two licensing contracts ended effective 17 April 2025; the agreement expressly identified Galderma Holding SA and Sol-Gel Technologies Ltd. of Ness Ziona, Israel, as the contracting parties.8
Sol-Gel’s 2026 corporate filing confirms that Galderma commercially marketed the products in the United States from 2022 until April 2025 and that the relevant US rights subsequently transferred to Mayne Pharma.9
The Sol-Gel relationship concerned prescription dermatology products and associated pharmaceutical intellectual property; the cited original agreements do not identify an Israeli cybersecurity, surveillance, enterprise cloud, or military software product supplied to Galderma.6, 8
Israeli distributor - Rafa Laboratories
In a company-authored public statement published approximately in 2022, Rafa Laboratories described Galderma representatives Robert Bitner, Veronika Dubitskaya, Monika Lamparska-Kania, and Karolina Zabuska visiting Israel and characterised Rafa’s role as a longstanding commercial partner for Galderma brands in the Israeli dermatology market.10
Rafa describes its business as importing, manufacturing, and marketing pharmaceutical products, including dermatology products, to public and private hospitals, healthcare organisations, clinics, and pharmacies in Israel; the statement does not identify which particular Galderma products were supplied to each institutional customer.11
An Israeli pharmaceutical directory also identifies Galderma among Rafa’s international pharmaceutical partners, corroborating the relationship independently of the social-media statement.12
No public evidence identified establishing that Rafa deployed Galderma-origin enterprise software or digital infrastructure for Israeli government institutions.
Procurement and systems integration
No public evidence identified establishing a named systems integrator that implemented Israeli-origin cybersecurity, analytics, surveillance, or cloud software within Galderma’s enterprise environment.
Technology dependency
Galderma identified FACE as a practitioner consultation and patient-management application, and its 2023 launch material described functionality for retaining treatment plans, appointment schedules, and patient images; published materials do not disclose the platform’s hosting region or its relationship to Galderma’s central enterprise infrastructure.1
No public evidence identified establishing that an Israeli-origin vendor operates a mission-critical element of Galderma’s enterprise technology stack.
Surveillance, Biometrics & Retail Technology
Facial imaging and assessment
Galderma’s January 2023 announcement states that FACE by Galderma incorporates digital facial assessment, wrinkle detection, augmented reality, and simulated treatment outcomes; the assessment considers facial shape, symmetry, proportions, contours, and animated expressions.1
The same announcement describes the application’s patient-management function, including storage of treatment plans, appointments, images, and videos, with patient access to an individual account.1
Galderma’s March 2023 US launch statement identifies facial assessment and aesthetic treatment simulation as the product’s intended clinical-consultation functions.2
The documented application is therefore a facial-analysis and image-processing product for aesthetic consultations; the cited product descriptions do not establish facial identification, biometric identity matching, or surveillance deployment.1, 2
Israeli-origin facial recognition
No public evidence identified connecting Galderma with Trigo, BriefCam, AnyVision/Oosto, Trax, or comparable Israeli-origin facial recognition or retail-surveillance suppliers.
Predictive monitoring and workforce surveillance
Galderma publicly describes predictive AI within its internal technology programme, but the company’s description concerns research, business trends, personalisation, and enterprise transformation rather than policing or workforce surveillance.4
No public evidence identified of Israeli-origin predictive policing, social-media surveillance, employee monitoring, or behavioural security platforms deployed by Galderma.
Third-party surveillance deployment
No public evidence identified establishing that a Galderma technology partner or managed-service provider deployed an Israeli-origin surveillance or biometric identification platform on Galderma’s behalf.
Retail and consumer analytics
Galderma’s 2023 CEO statement identifies Cetaphil AI Skin Analysis as an AI-supported tool intended to offer personalised skincare recommendations.5
No public evidence identified establishing that the Cetaphil tool uses Israeli-origin computer vision, facial recognition, or retail surveillance infrastructure.
Cloud Infrastructure, Data Residency & Sovereign Cloud Participation
Data centres and hosting in Israel
No public evidence identified establishing that Galderma owns, leases, or operates a data centre, cloud availability zone, or colocation facility in Israel.
Clinical and consumer data processing
Galderma’s January 2023 FACE announcement establishes that the application can retain treatment records, facial images and videos, schedules, and individual patient profiles.1
The March 2023 US announcement establishes that patients can access their individual profiles remotely through the application.2
These disclosures establish a patient-data-processing function but do not disclose the underlying physical hosting locations, international data-transfer routes, encryption arrangements, or subcontracted processors.1, 2
No public evidence identified establishing that Galderma’s FACE application transfers patient data to Israeli-operated infrastructure or makes such data available to Israeli state institutions.
Shareholder-group infrastructure
On 8 December 2025, L’Oréal announced the acquisition of an additional 10% of Galderma, bringing its intended total participation to 20% following completion.13
Galderma’s April 2026 AGM announcement confirmed the election of L’Oréal representatives Samuel du Retail and Delphine Viguier-Hovasse to Galderma’s board.14
L’Oréal’s Israeli corporate website describes approximately 300 employees and facilities in Netanya and Caesarea serving its own local operations.15
No public evidence identified establishing that these L’Oréal facilities host, process, or route Galderma customer, clinical, or enterprise data.
Project Nimbus and Israeli government cloud
No public evidence identified of Galderma’s participation in Project Nimbus, the provision of cloud infrastructure to Israeli government agencies, or direct service agreements involving Israeli sovereign cloud programmes.
Data sovereignty and resilience services
Galderma’s public partnership description focuses on dermatology research, therapeutic products, medical aesthetics, and healthcare-professional education.16
No public evidence identified establishing that Galderma markets data-sovereignty, government cloud, cyber-resilience, or secure infrastructure services to Israeli state or military bodies.
Defence, Intelligence & Security Sector Technology Relationships
Military and intelligence contracts
No public evidence identified establishing a technology contract between Galderma and the Israeli Ministry of Defence, Israel Defense Forces, Israeli intelligence agencies, or military technology procurement bodies.
Indirect healthcare-sector commercial relationships
Rafa Laboratories states that it supplies medicines to Israeli public hospitals and other healthcare institutions, while separately identifying Galderma among its international pharmaceutical partners.11, 12
The available disclosures do not identify Galderma-specific digital products sold through Rafa to military hospitals, security agencies, or defence procurement authorities.11, 12
Dual-use technology
FACE by Galderma is documented as an aesthetic consultation product using facial analysis and treatment simulation.1
No public evidence identified documenting use of FACE, Cetaphil AI Skin Analysis, or another Galderma digital product in military intelligence, law enforcement surveillance, border security, or population-monitoring systems.
Offensive cyber and digital weapons
No public evidence identified of Galderma developing, selling, licensing, or maintaining offensive cyber capabilities, exploit tools, spyware, electronic intelligence collection platforms, or digital weapons systems.
Military applications of pharmaceutical technology
Sol-Gel’s SEC-filed agreements and Galderma’s commercialisation arrangements concern treatments for acne and rosacea in the United States.6, 7
No public evidence identified establishing that the relationship supplied general-purpose military digital infrastructure or purpose-built weapons software.
AI, Algorithmic & Autonomous Systems
Commercial AI applications
Galderma announced in January 2023 that FACE by Galderma combined facial assessment and augmented-reality treatment visualisation with technology developed by Crisalix, whose published description refers to artificial intelligence and computer vision.1
Galderma’s 2023 CEO statement also identified Cetaphil AI Skin Analysis as an AI-powered skincare recommendation tool.5
In 2024, Galderma executive Gerry Muhle described AI and augmented reality as technologies supporting personalised aesthetic recommendations and stated that Galderma was developing its dermatology technology capabilities.3
In 2025, Galderma publicly described an AI Framework and AI Center of Excellence intended to support internal innovation, predictive analytics, generative AI, personalisation, and research activity.4
AI technology suppliers
Crisalix is a publicly identified development partner for the FACE application.1, 2
No public evidence identified establishing that the FACE partnership involved an Israeli AI supplier or Israeli-operated model infrastructure.
Data exposure and model training
FACE’s public description establishes the application’s handling of individual facial assessment information, treatment plans, and images.1
No public evidence identified establishing that these records were transferred to Israeli AI developers, used for Israeli military model training, or combined with Israeli surveillance-derived datasets.
Provision to state bodies
No public evidence identified of Galderma providing AI or machine-learning platforms to Israeli defence, intelligence, policing, or security institutions.
Autonomous systems and lethality
No public evidence identified of Galderma supplying autonomous target-generation software, fire-control systems, automated weapons engagement platforms, or purpose-built military targeting AI.
Technology Ecosystem & R&D Footprint
Corporate research and innovation
Galderma’s corporate history identifies its founding in 1981, subsequent dermatology-related acquisitions, its 2024 Swiss stock-market listing, and the development of medical and digital aesthetic products.17
The company’s partnerships page describes cooperation with research organisations and commercial partners in dermatology, aesthetics, therapeutic research, and healthcare-professional education.16
No public evidence identified establishing a Galderma-operated technology R&D laboratory, engineering centre, innovation accelerator, or data-processing research facility in Israel.
Israeli pharmaceutical technology partnership
In June 2021, Galderma entered into exclusive US commercialisation agreements with Israeli biotechnology company Sol-Gel Technologies for TWYNEO and EPSOLAY.6
Sol-Gel’s 2024 annual filing describes the relationship’s contractual consideration, royalty structure, and product manufacturing arrangements.7
Sol-Gel’s original pharmaceutical technology relationship with Galderma continued through 2024, with the companies subsequently signing an agreement effective 17 April 2025 terminating the US licensing rights.8
Sol-Gel’s 2026 filing separately identifies Beimei as having acquired commercialisation and manufacturing rights for TWYNEO covering Israel and several Asian markets in May 2024, while Galderma’s historical exclusive rights concerned the United States.9
Equity investments and corporate attribution
L’Oréal’s December 2025 announcement identifies Sunshine SwissCo, an EQT-led consortium, Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd. among the selling shareholder arrangements associated with its increased Galderma investment.13
Galderma’s April 2026 AGM approved board representation for L’Oréal following the increased investment.14
L’Oréal independently documents a commercial and operational presence in Israel, including offices and logistics activities.15
These corporate disclosures identify a major Galderma shareholder with Israeli operations but do not establish that Galderma itself owns or controls those Israeli facilities.13, 15
Named controlling principals
Galderma’s April 2026 AGM announcement identifies Thomas Ebeling as Chair and Flemming Ørnskov among the re-elected board members, alongside other elected board members and the newly elected L’Oréal representatives.14
No public evidence identified establishing that these named principals personally controlled, invested in, or held board positions in Israeli offensive cyber, military surveillance, SIGINT, or military AI companies.
Israeli acquisitions and venture investments
No public evidence identified establishing Galderma’s acquisition of an Israeli cybersecurity, AI, surveillance, cloud infrastructure, or defence technology company.
No public evidence identified establishing a Galderma strategic venture investment in an Israeli military technology fund.
Patents and academic partnerships
The Sol-Gel licensing agreements establish a commercial relationship involving an Israeli company’s proprietary pharmaceutical technology, rather than a documented jointly assigned Galderma–Israeli university patent portfolio.6, 7
No public evidence identified of a Galderma patent co-development agreement with Technion, the Hebrew University of Jerusalem, the Weizmann Institute, or another Israeli academic institution.
Civil Society Scrutiny & Regulatory History
UN and specialist NGO investigations
No public evidence identified in the investigated materials of a UN, Who Profits, AFSC Investigate, Amnesty International, Human Rights Watch, or comparable published investigation specifically establishing Galderma’s provision of digital surveillance, military AI, or Israeli government cloud services.
No independently verified Galderma-specific Digital entry was established from the investigated UN settlement-business reporting.
Boycott and divestment campaigns
No public evidence identified of an organised boycott or divestment campaign specifically naming Galderma for supplying cybersecurity, surveillance, military AI, or digital infrastructure to Israeli state institutions.
Regulatory and legal proceedings
No public evidence identified of a sanctions proceeding, export-control enforcement action, procurement challenge, or regulatory investigation involving Galderma’s provision of digital technology to Israeli defence or intelligence entities.
Documented Israeli commercial relationships
Rafa’s approximately 2022 partnership statement explicitly described the commercialisation of Galderma brands in Israel and identified visiting Galderma employees.10
Rafa’s published therapeutic-area description establishes a wider distribution business covering Israeli public and private healthcare institutions, although it does not specify Galderma-branded supply volumes or named state customers.11
Sol-Gel’s SEC-filed 2021 announcement establishes an Israeli biotechnology licensing relationship with Galderma for the US dermatology market.6
The relationship remained commercially active during 2024, as reflected in Sol-Gel’s financial disclosures.7
The SEC-filed termination agreement confirms that the Galderma–Sol-Gel licences were terminated effective 17 April 2025.8
Sol-Gel’s subsequent 2025 financial disclosure recorded royalties relating to the agreements and independently confirmed their termination in April 2025.18
Constructive-notice chronology
The Sol-Gel commercial relationship was established in June 2021 and remained active after 19 July 2024 and during the period following November 2024; the signed termination agreement establishes its end date as 17 April 2025.7, 8
The verified relationship involved dermatological pharmaceutical products and licensing rights, and the underlying agreements do not document provision of military, intelligence, or surveillance technology.6, 8
Settlement-related digital services
No public evidence identified establishing that Galderma supplied digital infrastructure, cybersecurity services, facial identification software, or other Digital products to Israeli settlements in the occupied Palestinian territory.
Israeli distribution and institutional customer coverage
Rafa’s corporate website identifies an operating address in Jerusalem and describes supply to Israeli public healthcare organisations, hospitals, clinics, and pharmacies.11
The available Rafa disclosures do not establish the presence of a Galderma-specific technology deployment, Israeli settlement branch, or particular Galderma product contract in an occupied territory.10, 11
Temporal status of principal relationships
The FACE application and Crisalix development partnership were publicly established in 2023, and Galderma continued publicly discussing the technology during 2024.1, 3
The Sol-Gel US licensing arrangements were active from June 2021 until 17 April 2025, when they were terminated.8, 9
L’Oréal’s increased strategic investment was announced in December 2025, and its nominated representatives were elected to Galderma’s board in April 2026.13, 14
Galderma’s 2025 annual-report webpage documents the company’s contemporary dermatology business and corporate reporting framework.19
Footnotes
-
Galderma, “Galderma announces the launch of FACE by Galderma,” 26 January 2023. https://www.galderma.com/news/galderma-announces-launch-face-galdermatm-game-changing-augmented-reality-solution-helping ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12
-
Galderma, “Galderma launches FACE by Galderma,” 22 March 2023. https://www.galderma.com/news/galderma-launches-face-galdermatm-cutting-edge-aesthetic-visualization-tool-simulates ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Galderma, “Shaping the future: Gerry Muhle on the technologies driving dermatology,” 2024. https://www.galderma.com/news/shaping-future-gerry-muhle-technologies-driving-dermatology ↩ ↩2 ↩3
-
Galderma, “Advancing the future of dermatology with robust IT,” 2025. https://www.galderma.com/news/advancing-future-dermatology-robust-it ↩ ↩2 ↩3
-
Galderma, “Foreword from Galderma CEO Flemming Ørnskov,” 2023. https://www.galderma.com/foreword-ceo-2023 ↩ ↩2 ↩3
-
Sol-Gel Technologies and Galderma, “Exclusive licenses for the commercialization of EPSOLAY and TWYNEO,” SEC Exhibit 99.1, 28 June 2021. https://www.sec.gov/Archives/edgar/data/1684693/000117891321002157/exhibit_99-1.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
-
Sol-Gel Technologies, SEC annual filing, 2024, including licensing and royalty disclosures. https://www.sec.gov/Archives/edgar/data/1684693/000117891324000932/zk2431086.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Galderma Holding SA and Sol-Gel Technologies Ltd., Termination Agreement effective 17 April 2025, SEC Exhibit 4.17. https://www.sec.gov/Archives/edgar/data/1684693/000117891325001497/exhibit_4-17.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
-
Sol-Gel Technologies, SEC annual filing, 2026, including historical Galderma licensing arrangements and transfer of US commercialisation rights. https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/zk2634571.htm ↩ ↩2 ↩3
-
Rafa Laboratories, company-authored LinkedIn statement describing Galderma partnership and visiting representatives, approximately 2022. https://www.linkedin.com/posts/rafa-labartories_galderma-activity-6917069901069197312-X89M ↩ ↩2 ↩3
-
Rafa Laboratories, “Therapeutic Areas,” company website, accessed 25 October 2026. https://www.rafa.co.il/en/therapeutic-areas ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Medic, “Rafa Laboratories Ltd,” pharmaceutical distributor profile, accessed 25 October 2026. https://medic.co.il/license-holder/rafa-laboratories-ltd/ ↩ ↩2 ↩3
-
L’Oréal Finance, “L’Oréal Groupe to reinforce its strategic investment in Galderma,” 8 December 2025. https://www.loreal-finance.com/eng/press-release/loreal-groupe-reinforce-its-strategic-investment-galderma-additional-10-bringing-its ↩ ↩2 ↩3 ↩4
-
Galderma, “Galderma shareholders approve all Annual General Meeting proposals,” 22 April 2026. https://www.galderma.com/news/galderma-annual-general-meeting-2026 ↩ ↩2 ↩3 ↩4
-
L’Oréal Groupe, “Israel,” corporate country profile, accessed 25 October 2026. https://www.loreal.com/en/israel/ ↩ ↩2 ↩3
-
Galderma, “Partnerships,” company website, accessed 25 October 2026. https://www.galderma.com/partnerships ↩ ↩2
-
Galderma, “At a Glance,” corporate history, accessed 25 October 2026. https://www.galderma.com/glance ↩
-
Sol-Gel Technologies, SEC financial disclosure, 2025, including royalty revenue and April 2025 termination. https://www.sec.gov/Archives/edgar/data/1684693/000117891325002946/exhibit_99-2.htm ↩
-
Galderma, “Annual Report 2025,” corporate reporting page, 2026. https://www.galderma.com/annual-report-2025 ↩